William Coley was an unacclaimed hero of early cancer treatment. His work is often overshadowed by more recent advancements in immunotherapy. Coley's innovative work in the 1910s and 1930s laid the groundwork for what would become a major field in oncology. His experiments with bacterial vaccines by making use of the immune system to combat cancer preceded contemporary immunotherapy for several decades. This review provides a comprehensive exploration of Coley's life, his groundbreaking research, the socio-scientific challenges he faced, and his lasting impact on cancer treatment. Even though he faced lots of initial resistance and challenges, Coley's work has influenced modern immunotherapy practices.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466495 | PMC |
| http://dx.doi.org/10.7759/cureus.69113 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Temporal evaluation of lung injury following chlorine Inhalation in a ventilated pig model.
Inhal Toxicol
December 2024
Center for Advanced Drug Development, Department of Pediatrics, School of Medicine, University of Colorado, Aurora, CO, USA.
Article Synopsis
- Chlorine (Cl) exposure can cause serious lung injuries, and this study aimed to create a model using swine to better understand these injuries and their progression.
- The research involved anesthetizing and exposing male swine to Cl, leading to significant respiratory issues and a high mortality rate shortly after exposure.
- The findings suggest key markers for assessing lung injury and recovery, highlighting the importance of early histopathological evaluations in developing medical countermeasures against chlorine-induced lung damage.
Copper-carbon hybrid nanoparticles as antimicrobial additives.
MRS Commun
October 2022
Department of Chemistry, University of California, Riverside, CA 92521 USA.
Unlabelled: Millions of cases of hospital-acquired infections occur every year involving difficult to treat bacterial and fungal agents. In an effort to improve patient outcomes and provide better infection control, antimicrobial coatings are ideal to apply in clinical settings in addition to aseptic practices. Most efforts involving effective antimicrobial surface technologies are limited by toxicity of exposure due to the diffusion.
View Article and Find Full Text PDFSystemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical Countermeasure.
J Med Toxicol
July 2022
High Point Clinical Trials Center, 4160 Mendenhall Oaks Pkwy #105, High Point, NC, 27265, USA.
Introduction: Atropine sulfate is an FDA-approved medical countermeasure (MCM) for the treatment of organophosphorus nerve agent and organophosphate pesticide toxicity. Sufficient MCM supplies must be available in an incident involving a mass human exposure either from an accidental chemical release or a terrorist attack.
Methods: We performed a randomized, 3-sequence, 3-period phase I crossover study to assess the bioavailability and pharmacokinetics (PK) of a single dose (0.
Loss of Zbtb32 in NOD mice does not significantly alter T cell responses.
F1000Res
August 2019
Immune Tolerance Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda , MD, 20892, USA.
We previously identified the transcriptional regulator Zbtb32 as a factor that can promote T cell tolerance in the Non-Obese Diabetic (NOD) mouse, a model of Type 1 diabetes. Antigen targeted to DCIR2 dendritic cells (DCs) inhibited both diabetes and effector T cell expansion in NOD mice. Furthermore, Zbtb32 was preferentially induced in autoreactive CD4 T cells stimulated by these tolerogenic DCIR2 DCs, and overexpression of Zbtb32 in islet-specific T cells inhibited the diabetes development by limiting T cell proliferation and cytokine production.
View Article and Find Full Text PDFLow CD25 on autoreactive Tregs impairs tolerance via low dose IL-2 and antigen delivery.
J Autoimmun
June 2018
Immune Tolerance Section, Diabetes, Endocrinology and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA. Electronic address:
Dendritic cell (DC)-mediated T cell tolerance deficiencies contribute to the pathogenesis of autoimmune diseases such as type 1 diabetes. Delivering self-antigen to dendritic-cell inhibitory receptor-2 (DCIR2) DCs can delay but not completely block diabetes development in NOD mice. These DCIR2-targeting antibodies induce tolerance via deletion and anergy, but do not increase islet-specific Tregs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!